• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用 drugZ 从 CRISPR 筛选中鉴定化学生物遗传学相互作用。

Identifying chemogenetic interactions from CRISPR screens with drugZ.

机构信息

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

UTHealth Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Genome Med. 2019 Aug 22;11(1):52. doi: 10.1186/s13073-019-0665-3.

DOI:10.1186/s13073-019-0665-3
PMID:31439014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6706933/
Abstract

BACKGROUND

Chemogenetic profiling enables the identification of gene mutations that enhance or suppress the activity of chemical compounds. This knowledge provides insights into drug mechanism of action, genetic vulnerabilities, and resistance mechanisms, all of which may help stratify patient populations and improve drug efficacy. CRISPR-based screening enables sensitive detection of drug-gene interactions directly in human cells, but until recently has primarily been used to screen only for resistance mechanisms.

RESULTS

We present drugZ, an algorithm for identifying both synergistic and suppressor chemogenetic interactions from CRISPR screens. DrugZ identifies synthetic lethal interactions between PARP inhibitors and both known and novel members of the DNA damage repair pathway, confirms KEAP1 loss as a resistance factor for ERK inhibitors in oncogenic KRAS backgrounds, and defines the genetic context for temozolomide activity.

CONCLUSIONS

DrugZ is an open-source Python software for the analysis of genome-scale drug modifier screens. The software accurately identifies genetic perturbations that enhance or suppress drug activity. Interestingly, analysis of new and previously published data reveals tumor suppressor genes are drug-agnostic resistance genes in drug modifier screens. The software is available at github.com/hart-lab/drugz .

摘要

背景

化学遗传学分析能够鉴定出增强或抑制化合物活性的基因突变。这些知识为药物作用机制、遗传脆弱性和耐药机制提供了深入的了解,所有这些都可能有助于对患者群体进行分层,并提高药物疗效。基于 CRISPR 的筛选能够在人类细胞中直接灵敏地检测药物-基因相互作用,但直到最近,它主要用于筛选耐药机制。

结果

我们提出了 drugZ,这是一种从 CRISPR 筛选中识别协同和抑制性化学遗传学相互作用的算法。DrugZ 鉴定了 PARP 抑制剂与 DNA 损伤修复途径中已知和新的成员之间的合成致死相互作用,证实 KEAP1 缺失是致癌性 KRAS 背景下 ERK 抑制剂的耐药因素,并定义了替莫唑胺活性的遗传背景。

结论

DrugZ 是一个用于分析全基因组药物修饰筛选的开源 Python 软件。该软件能够准确识别增强或抑制药物活性的遗传扰动。有趣的是,对新的和以前发表的数据的分析表明,在药物修饰筛选中,肿瘤抑制基因是无药物特异性的耐药基因。该软件可在 github.com/hart-lab/drugz 获得。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/d5ade4978da9/13073_2019_665_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/bcebd710cfbb/13073_2019_665_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/a6c03ed6d349/13073_2019_665_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/6d9710a9ffb4/13073_2019_665_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/d5ade4978da9/13073_2019_665_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/bcebd710cfbb/13073_2019_665_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/a6c03ed6d349/13073_2019_665_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/6d9710a9ffb4/13073_2019_665_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/6706933/d5ade4978da9/13073_2019_665_Fig4_HTML.jpg

相似文献

1
Identifying chemogenetic interactions from CRISPR screens with drugZ.利用 drugZ 从 CRISPR 筛选中鉴定化学生物遗传学相互作用。
Genome Med. 2019 Aug 22;11(1):52. doi: 10.1186/s13073-019-0665-3.
2
Genome-wide CRISPR screens using isogenic cells reveal vulnerabilities conferred by loss of tumor suppressors.使用同基因细胞进行的全基因组CRISPR筛选揭示了肿瘤抑制因子缺失所赋予的脆弱性。
Sci Adv. 2022 May 13;8(19):eabm6638. doi: 10.1126/sciadv.abm6638.
3
GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens.Gemini:一种从组合 CRISPR 筛选中识别遗传相互作用的变分贝叶斯方法。
Genome Biol. 2019 Jul 12;20(1):137. doi: 10.1186/s13059-019-1745-9.
4
DrugThatGene: integrative analysis to streamline the identification of druggable genes, pathways and protein complexes from CRISPR screens.DrugThatGene:从 CRISPR 筛选中简化鉴定可成药基因、途径和蛋白质复合物的综合分析。
Bioinformatics. 2019 Jun 1;35(11):1981-1984. doi: 10.1093/bioinformatics/bty913.
5
Chemogenetic interactions in human cancer cells.人类癌细胞中的化学遗传学相互作用。
Comput Struct Biotechnol J. 2019 Oct 26;17:1318-1325. doi: 10.1016/j.csbj.2019.09.006. eCollection 2019.
6
Guide assignment in single-cell CRISPR screens using crispat.利用 crispat 在单细胞 CRISPR 筛选中进行指导分配。
Bioinformatics. 2024 Sep 2;40(9). doi: 10.1093/bioinformatics/btae535.
7
CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions.CRISPR 筛选提供了对癌症易损性的全面评估,但对高度扩增的基因组区域产生了假阳性结果。
Cancer Discov. 2016 Aug;6(8):900-13. doi: 10.1158/2159-8290.CD-16-0178. Epub 2016 Jun 3.
8
Albumin-conjugated drug is irresistible by single gene mutation of endocytic system: Verification by genome-wide CRISPR-Cas9 loss-of-function screens.白蛋白结合药物不可抗拒的内吞系统单基因突变:全基因组 CRISPR-Cas9 基因敲除筛选的验证。
J Control Release. 2020 Jul 10;323:311-320. doi: 10.1016/j.jconrel.2020.04.035. Epub 2020 Apr 24.
9
A CRISPR Platform for Targeted In Vivo Screens.用于体内靶向筛选的CRISPR平台。
Methods Mol Biol. 2023;2614:397-409. doi: 10.1007/978-1-0716-2914-7_24.
10
Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.细胞间 CRISPR 筛选发现癌症免疫治疗靶点
Front Immunol. 2022 May 16;13:884561. doi: 10.3389/fimmu.2022.884561. eCollection 2022.

引用本文的文献

1
An unexpected role of CLASP1 in radiation response and S-phase regulation of head and neck cancer cells.CLASP1在头颈癌细胞的辐射反应和S期调控中的意外作用。
PLoS One. 2025 Aug 6;20(8):e0329731. doi: 10.1371/journal.pone.0329731. eCollection 2025.
2
The PLK4 inhibitor RP-1664 demonstrates potent single-agent efficacy in neuroblastoma models through a dual mechanism of sensitivity.PLK4抑制剂RP-1664通过双重敏感机制在神经母细胞瘤模型中显示出强大的单药疗效。
Res Sq. 2025 Jul 29:rs.3.rs-7014295. doi: 10.21203/rs.3.rs-7014295/v1.
3
The RING finger E3 ligase RNF25 protects DNA replication forks independently of its canonical roles in ubiquitin signaling.

本文引用的文献

1
Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells.全基因组 CRISPR-Cas9 筛选揭示胶质母细胞瘤干细胞对替莫唑胺敏感性的遗传脆弱性和机制。
Cell Rep. 2019 Apr 16;27(3):971-986.e9. doi: 10.1016/j.celrep.2019.03.047.
2
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.利用 CRISPR-Cas9 筛选技术对癌症治疗靶点进行优先级排序。
Nature. 2019 Apr;568(7753):511-516. doi: 10.1038/s41586-019-1103-9. Epub 2019 Apr 10.
3
Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
环状结构域E3连接酶RNF25独立于其在泛素信号传导中的经典作用来保护DNA复制叉。
Nat Commun. 2025 Aug 5;16(1):7214. doi: 10.1038/s41467-025-62368-8.
4
Unraveling resistance mechanisms to the novel nucleoside analog RX-3117 in lung cancer: insights into DNA repair, cell cycle dysregulation and targeting PKMYT1 for improved therapy.解析肺癌对新型核苷类似物RX-3117的耐药机制:对DNA修复、细胞周期失调及靶向PKMYT1以改善治疗的见解
J Exp Clin Cancer Res. 2025 Jul 24;44(1):217. doi: 10.1186/s13046-025-03470-z.
5
Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors.线粒体代谢受损是MYC抑制剂的关键癌症易感性因素。
Sci Adv. 2025 Jul 18;11(29):eadw5228. doi: 10.1126/sciadv.adw5228. Epub 2025 Jul 16.
6
Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastoma.靶向极高风险髓母细胞瘤中非同源末端连接与放疗之间的合成致死效应。
Cell Rep Med. 2025 Jul 15;6(7):102202. doi: 10.1016/j.xcrm.2025.102202. Epub 2025 Jun 24.
7
USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance.USP37通过抵消HLTF来保护受损的复制叉,并促进BRCA1缺陷细胞的存活和对PARP抑制剂的抗性。
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf544.
8
USP37 prevents premature disassembly of stressed replisomes by TRAIP.USP37可防止TRAIP介导的应激复制体过早解体。
Nat Commun. 2025 Jun 18;16(1):5333. doi: 10.1038/s41467-025-60139-z.
9
CRAMP1-dependent histone H1 biogenesis is essential for topoisomerase II inhibitor tolerance.CRAMP1依赖性组蛋白H1生物合成对于拓扑异构酶II抑制剂耐受性至关重要。
Mol Cell. 2025 Jul 3;85(13):2487-2502.e12. doi: 10.1016/j.molcel.2025.04.006. Epub 2025 Jun 13.
10
A genome-wide in vivo CRISPR screen identifies neuroprotective strategies in the mouse and human retina.全基因组体内CRISPR筛选确定了小鼠和人类视网膜中的神经保护策略。
bioRxiv. 2025 Mar 24:2025.03.22.644712. doi: 10.1101/2025.03.22.644712.
全基因组 CRISPR 筛选揭示了 RNASEH2 缺陷和 ATR 抑制的合成致死性。
Oncogene. 2019 Apr;38(14):2451-2463. doi: 10.1038/s41388-018-0606-4. Epub 2018 Dec 7.
4
53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ.53BP1 与 REV7-shieldin 复合物的合作是 DNA 结构特异性 NHEJ 的基础。
Nature. 2018 Aug;560(7716):122-127. doi: 10.1038/s41586-018-0362-1. Epub 2018 Jul 25.
5
The shieldin complex mediates 53BP1-dependent DNA repair.屏蔽复合物介导 53BP1 依赖性 DNA 修复。
Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18.
6
53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polα-dependent fill-in.53BP1-RIF1-shieldin 通过 CST 和 Polα 依赖性填补来阻止 DSB 切除。
Nature. 2018 Aug;560(7716):112-116. doi: 10.1038/s41586-018-0324-7. Epub 2018 Jul 18.
7
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.Shieldin 复合物促进 DNA 末端连接,并在 BRCA1 缺失细胞中对抗同源重组。
Nat Cell Biol. 2018 Aug;20(8):954-965. doi: 10.1038/s41556-018-0140-1. Epub 2018 Jul 18.
8
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.CRISPR 筛选鉴定基因组核糖核苷酸为 PARP 捕获损伤的来源。
Nature. 2018 Jul;559(7713):285-289. doi: 10.1038/s41586-018-0291-z. Epub 2018 Jul 4.
9
Dual direction CRISPR transcriptional regulation screening uncovers gene networks driving drug resistance.双向 CRISPR 转录调控筛选揭示了驱动耐药性的基因网络。
Sci Rep. 2017 Dec 18;7(1):17693. doi: 10.1038/s41598-017-18172-6.
10
Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells.拷贝数效应的计算校正提高了CRISPR-Cas9在癌细胞中必需性筛选的特异性。
Nat Genet. 2017 Dec;49(12):1779-1784. doi: 10.1038/ng.3984. Epub 2017 Oct 30.